M. Marc Abreu

M. Marc Abreu

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
M. Marc AbreuM. Marc Abreu
M. Marc Abreu
ACAlberto F. Chocron
Alberto F. Chocron
DSDavid M Smadja
David M Smadja
The emergence of immunotherapies has revolutionized cancer treatment by leveraging the immune system to target malignancies, offering new hope where traditional therapies often fall short. Within this context, hyperthermia (HT) has re-emerged as a promising adjunctive treatment, capable of enhancing the effectiveness of radiotherapy, chemotherapy, and immunotherapy. HT influences both the innate and adaptive immune systems, enhancing the activity of immune cells such as neutrophils, NK cells, and dendritic cells, while also modulating the tumor microenvironment (TME) to promote immunogenic cell death (ICD) and reduce immunosuppressive conditions. These effects contribute to the transformation of immunologically “cold” tumors into “hot” tumors, making them more susceptible to immune-mediated destruction. Furthermore, HT can amplify the efficacy of immune checkpoint inhibitors (ICIs) by improving immune cell infiltration, inducing damage-associated molecular pattern (DAMP) release, and enhancing antigen presentation. Preclinical and clinical studies support the combination of HT with ICIs, demonstrating improved outcomes in otherwise resistant tumors. However, the full therapeutic potential of the different technologies allowing to apply HT remains to be fully understood, and further research is needed to optimize treatment protocols, explore the differential impacts of local versus whole-body hyperthermia, and identify biomarkers for patient stratification. This review underscores the multifaceted role of HT in immunity and its potential to significantly enhance the efficacy of immunotherapy.

15 June 2019 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
LRLuiz Csp Rolim
Luiz Csp Rolim
ESEdina Mk Da Silva
Edina Mk Da Silva
RFRonald Lg Flumignan
Ronald Lg Flumignan
M. Marc AbreuM. Marc Abreu
M. Marc Abreu
SDSérgio A Dib
Sérgio A Dib

1 August 1998 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
AAAugusto Azuara-Blanco
Augusto Azuara-Blanco
AHAlon Harris
Alon Harris
LCLouis B Cantor
Louis B Cantor
M. Marc AbreuM. Marc Abreu
M. Marc Abreu
MWMonika Weinland
Monika Weinland
AIMS To evaluate the effect of acute elevation of intraocular pressure (IOP) on optic disc cupping. METHODS 10 emmetropic and 10 myopic volunteers were included in this study. The cup area (CA) and cup volume (CV) of the optic disc were determined with the Heidelberg retina tomograph (HRT). After baseline determinations, a suction cup was used to increase the intraocular pressure (IOP) to 20–25 mm Hg above the baseline and HRT images were obtained. RESULTS Baseline IOP was 13.5 (SD 1.3) mm Hg and 12.6 (2.6) mm Hg in the emmetropic and myopic groups, respectively. The IOP was elevated to 35.4 (3.3) mm Hg and 34.4 (2.5) mm Hg in the emmetropic and myopic groups, respectively. When compared with their baseline values, the cupping variables (CA and CV) were significantly increased (p<0.05) during the suction treatment in both emmetropic and myopic subjects. CONCLUSION There was a significant enlargement in the optic disc cupping during the artificial increment of intraocular pressure in both emmetropic and myopic eyes. In non-glaucomatous eyes the optic nerve head has a partially dynamic topography dependent upon the level of IOP.

1 December 1998 in Ophthalmology
Verified
Journal Article
Closed access
M. Marc AbreuM. Marc Abreu
M. Marc Abreu
YKYong Y Kim
Yong Y Kim
DSDong H Shin
Dong H Shin
PNPeter A Netland
Peter A Netland

4 February 2025 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
DSDavid M Smadja
David M Smadja
M. Marc AbreuM. Marc Abreu
M. Marc Abreu
Neurodegenerative diseases (NDs) and Long COVID represent critical and growing global health challenges, characterized by complex pathophysiological mechanisms including neuronal deterioration, protein misfolding, and persistent neuroinflammation. The emergence of innovative therapeutic approaches, such as whole-body hyperthermia (WBH), offers promising potential to modulate underlying pathophysiological mechanisms in NDs and related conditions like Long COVID. WBH, particularly in fever-range, enhances mitochondrial function, induces heat shock proteins (HSPs), and modulates neuroinflammation—benefits that pharmacological treatments often struggle to replicate. HSPs such as HSP70 and HSP90 play pivotal roles in protein folding, aggregation prevention, and cellular protection, directly targeting pathological processes seen in NDs like Alzheimer's, Parkinson's, and Huntington's disease. Preliminary findings also suggest WBH's potential to alleviate neurological symptoms in Long COVID, where persistent neuroinflammation and serotonin dysregulation are prominent. Despite the absence of robust clinical trials, the therapeutic implications of WBH extend to immune modulation and the restoration of disrupted physiological pathways. However, the dual nature of hyperthermia's effects—balancing pro-inflammatory and anti-inflammatory responses—emphasizes the need for dose-controlled applications and stringent patient monitoring to minimize risks in vulnerable populations. While WBH shows potential interest, significant challenges remain. These include individual variability in response, limited accessibility to advanced hyperthermia technologies, and the need for standardized clinical protocols. Future research must focus on targeted clinical trials, biomarker identification, and personalized treatment strategies to optimize WBH's efficacy in NDs and Long COVID. The integration of WBH into therapeutic paradigms could mark a transformative step in addressing these complex conditions.

1 November 1998 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
YKYong Y. Kim
Yong Y. Kim
BGBernice K. Glover
Bernice K. Glover
DSDong H. Shin
Dong H. Shin
DLDamho Lee
Damho Lee
RFRonald E.P. Frenkel
Ronald E.P. Frenkel
M. Marc AbreuM. Marc Abreu
M. Marc Abreu